000 | 04394nam a22005897a 4500 | ||
---|---|---|---|
001 | sulb-eb0025160 | ||
003 | BD-SySUS | ||
005 | 20160413122513.0 | ||
007 | cr nn 008mamaa | ||
008 | 131004s2013 gw | s |||| 0|eng d | ||
020 |
_a9783642386640 _9978-3-642-38664-0 |
||
024 | 7 |
_a10.1007/978-3-642-38664-0 _2doi |
|
050 | 4 | _aRM1-950 | |
072 | 7 |
_aMMG _2bicssc |
|
072 | 7 |
_aMED071000 _2bisacsh |
|
082 | 0 | 4 |
_a615 _223 |
245 | 1 | 0 |
_aPharmacotherapy of Pulmonary Hypertension _h[electronic resource] / _cedited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch. |
264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2013. |
|
300 |
_aIX, 576 p. 66 illus., 56 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v218 |
|
505 | 0 | _aPreface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions. | |
520 | _aThis volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aLaboratory medicine. | |
650 | 0 | _aMolecular biology. | |
650 | 0 | _aPharmacology. | |
650 | 0 | _aPharmaceutical technology. | |
650 | 0 | _aInternal medicine. | |
650 | 0 |
_aRespiratory organs _xDiseases. |
|
650 | 1 | 4 | _aBiomedicine. |
650 | 2 | 4 | _aPharmacology/Toxicology. |
650 | 2 | 4 | _aPharmaceutical Sciences/Technology. |
650 | 2 | 4 | _aInternal Medicine. |
650 | 2 | 4 | _aPneumology/Respiratory System. |
650 | 2 | 4 | _aLaboratory Medicine. |
650 | 2 | 4 | _aMolecular Medicine. |
700 | 1 |
_aHumbert, Marc. _eeditor. |
|
700 | 1 |
_aEvgenov, Oleg V. _eeditor. |
|
700 | 1 |
_aStasch, Johannes-Peter. _eeditor. |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9783642386633 |
830 | 0 |
_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v218 |
|
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-642-38664-0 |
912 | _aZDB-2-SBL | ||
942 |
_2Dewey Decimal Classification _ceBooks |
||
999 |
_c47252 _d47252 |